Table 1. Open in new tab Characteristics...

Pediatric: Individual patient data (n = 32)/Aggregate: (n = 25)	Adult: Individual patient data (n = 47)/Aggregate (n = 12)
Sex (m/f)	17/14	Sex (m/f)	21/20
Positive CNS status at initial diagnoses/out of total patients	IDP: N = 7/25^a (5 missing data) Aggregate: n = 8/25^a	Positive CNS status at initial diagnoses/out of total patients	IDP: N = 23/47^a Aggregate: n = 8/12^a
Primary malignancy	IDP: ALL n = 17, AML n = 2, Burkitt n = 12, CNS Lymphoma n = 1 Aggregate: B/T ALL n = 15, ALL n = 8^b, Burkitt n = 2	Primary malignancy	IDP: ALL n = 23, AML n = 3, NH n = 1, DLBCL n = 14, T-LBL n = 1, BPD n = 1, MALT n = 1, TCL n = 1, FL n = 1, LPL n = 1 Aggregate: PCNLS n = 8, ALL n = 4^b
MRI results +/total	IDP: myelopathy n = 8/23, radiculopathy n = 4/9 Aggregate: myelopathy: n = 4/7³⁹; radiculopathy: n = 0/8³⁹	MRI results	IDP: myelopathy n = 11/30, radiculopathy n = 10/17 Aggregate: radiculopathy: 0/8⁴⁰
Time of onset^c (1) days after first IT, (2) days after last IT	(1) Median of 14 days, (2) <10 days after their last IT injection (median of 6; range: 3-11) Aggregate: 10 IT, symptoms occurred 13 days after last IT	Time of onset^c (1) days after first IT, (2) days after last IT	(1) Median 10.5 days after first IT, (2) 10 days after a median of 6 IT injections Aggregate: second IT and within 5 months after the last injection

Pediatric: Individual patient data (n = 32)/Aggregate: (n = 25)

Adult: Individual patient data (n = 47)/Aggregate (n = 12)

Age

Mean = 10.4 y
Range: 1-18

Age

Mean = 44.1 y
Range: 21–80

Sex (m/f)

17/14

Sex (m/f)

21/20

Positive CNS status at initial diagnoses/out of total patients

IDP: N = 7/25^a (5 missing data)
Aggregate: n = 8/25^a

Positive CNS status at initial diagnoses/out of total patients

IDP: N = 23/47^a
Aggregate: n = 8/12^a

Primary malignancy

IDP: ALL n = 17, AML n = 2, Burkitt n = 12, CNS Lymphoma n = 1
Aggregate: B/T ALL n = 15, ALL n = 8^b, Burkitt n = 2

Primary malignancy

IDP: ALL n = 23, AML n = 3, NH n = 1, DLBCL n = 14, T-LBL n = 1, BPD n = 1, MALT n = 1, TCL n = 1, FL n = 1, LPL n = 1
Aggregate: PCNLS n = 8, ALL n = 4^b

MRI results +/total

IDP: myelopathy n = 8/23, radiculopathy n = 4/9
Aggregate: myelopathy: n = 4/7³⁹; radiculopathy: n = 0/8³⁹

MRI results

IDP: myelopathy n = 11/30, radiculopathy n = 10/17
Aggregate: radiculopathy: 0/8⁴⁰

Time of onset^c (1) days after first IT, (2) days after last IT

(1) Median of 14 days, (2) <10 days after their last IT injection (median of 6; range: 3-11)
Aggregate: 10 IT, symptoms occurred 13 days after last IT

Time of onset^c (1) days after first IT, (2) days after last IT

(1) Median 10.5 days after first IT, (2) 10 days after a median of 6 IT injections
Aggregate: second IT and within 5 months after the last injection

Pediatric: Individual patient data (n = 32)/Aggregate: (n = 25)	Adult: Individual patient data (n = 47)/Aggregate (n = 12)
Sex (m/f)	17/14	Sex (m/f)	21/20
Positive CNS status at initial diagnoses/out of total patients	IDP: N = 7/25^a (5 missing data) Aggregate: n = 8/25^a	Positive CNS status at initial diagnoses/out of total patients	IDP: N = 23/47^a Aggregate: n = 8/12^a
Primary malignancy	IDP: ALL n = 17, AML n = 2, Burkitt n = 12, CNS Lymphoma n = 1 Aggregate: B/T ALL n = 15, ALL n = 8^b, Burkitt n = 2	Primary malignancy	IDP: ALL n = 23, AML n = 3, NH n = 1, DLBCL n = 14, T-LBL n = 1, BPD n = 1, MALT n = 1, TCL n = 1, FL n = 1, LPL n = 1 Aggregate: PCNLS n = 8, ALL n = 4^b
MRI results +/total	IDP: myelopathy n = 8/23, radiculopathy n = 4/9 Aggregate: myelopathy: n = 4/7³⁹; radiculopathy: n = 0/8³⁹	MRI results	IDP: myelopathy n = 11/30, radiculopathy n = 10/17 Aggregate: radiculopathy: 0/8⁴⁰
Time of onset^c (1) days after first IT, (2) days after last IT	(1) Median of 14 days, (2) <10 days after their last IT injection (median of 6; range: 3-11) Aggregate: 10 IT, symptoms occurred 13 days after last IT	Time of onset^c (1) days after first IT, (2) days after last IT	(1) Median 10.5 days after first IT, (2) 10 days after a median of 6 IT injections Aggregate: second IT and within 5 months after the last injection

Table 1.

Open in new tab

Characteristics of the Final 116 Included PIPS Patients

Pediatric: Individual patient data (n = 32)/Aggregate: (n = 25)		Adult: Individual patient data (n = 47)/Aggregate (n = 12)
Age	Mean = 10.4 y Range: 1-18	Age	Mean = 44.1 y Range: 21–80
Sex (m/f)	17/14	Sex (m/f)	21/20
Positive CNS status at initial diagnoses/out of total patients	IDP: N = 7/25^a (5 missing data) Aggregate: n = 8/25^a	Positive CNS status at initial diagnoses/out of total patients	IDP: N = 23/47^a Aggregate: n = 8/12^a
Primary malignancy	IDP: ALL n = 17, AML n = 2, Burkitt n = 12, CNS Lymphoma n = 1 Aggregate: B/T ALL n = 15, ALL n = 8^b, Burkitt n = 2	Primary malignancy	IDP: ALL n = 23, AML n = 3, NH n = 1, DLBCL n = 14, T-LBL n = 1, BPD n = 1, MALT n = 1, TCL n = 1, FL n = 1, LPL n = 1 Aggregate: PCNLS n = 8, ALL n = 4^b
MRI results +/total	IDP: myelopathy n = 8/23, radiculopathy n = 4/9 Aggregate: myelopathy: n = 4/7³⁹; radiculopathy: n = 0/8³⁹	MRI results	IDP: myelopathy n = 11/30, radiculopathy n = 10/17 Aggregate: radiculopathy: 0/8⁴⁰
Time of onset^c (1) days after first IT, (2) days after last IT	(1) Median of 14 days, (2) <10 days after their last IT injection (median of 6; range: 3-11) Aggregate: 10 IT, symptoms occurred 13 days after last IT	Time of onset^c (1) days after first IT, (2) days after last IT	(1) Median 10.5 days after first IT, (2) 10 days after a median of 6 IT injections Aggregate: second IT and within 5 months after the last injection

Pediatric: Individual patient data (n = 32)/Aggregate: (n = 25)		Adult: Individual patient data (n = 47)/Aggregate (n = 12)
Age	Mean = 10.4 y Range: 1-18	Age	Mean = 44.1 y Range: 21–80
Sex (m/f)	17/14	Sex (m/f)	21/20
Positive CNS status at initial diagnoses/out of total patients	IDP: N = 7/25^a (5 missing data) Aggregate: n = 8/25^a	Positive CNS status at initial diagnoses/out of total patients	IDP: N = 23/47^a Aggregate: n = 8/12^a
Primary malignancy	IDP: ALL n = 17, AML n = 2, Burkitt n = 12, CNS Lymphoma n = 1 Aggregate: B/T ALL n = 15, ALL n = 8^b, Burkitt n = 2	Primary malignancy	IDP: ALL n = 23, AML n = 3, NH n = 1, DLBCL n = 14, T-LBL n = 1, BPD n = 1, MALT n = 1, TCL n = 1, FL n = 1, LPL n = 1 Aggregate: PCNLS n = 8, ALL n = 4^b
MRI results +/total	IDP: myelopathy n = 8/23, radiculopathy n = 4/9 Aggregate: myelopathy: n = 4/7³⁹; radiculopathy: n = 0/8³⁹	MRI results	IDP: myelopathy n = 11/30, radiculopathy n = 10/17 Aggregate: radiculopathy: 0/8⁴⁰
Time of onset^c (1) days after first IT, (2) days after last IT	(1) Median of 14 days, (2) <10 days after their last IT injection (median of 6; range: 3-11) Aggregate: 10 IT, symptoms occurred 13 days after last IT	Time of onset^c (1) days after first IT, (2) days after last IT	(1) Median 10.5 days after first IT, (2) 10 days after a median of 6 IT injections Aggregate: second IT and within 5 months after the last injection

Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; NH, non-Hodgkin; DLBCL, diffuse large B cell lymphoma; T-LBL, T cell lymphoblastic leukemia; BPD, blastic plasmacytoid dendritic cell neoplasm; MALT, mucosa-associated lymphoid tissue; TCL, T cell lymphoma; FL, follicular lymphoma; PCNLS, primary CNS lymphoma; LPL, lymph plasmatic lymphoma; IDP, Individual patient data.

^aAll patients were negative for CNS involvement at the time of onset of the neurological symptoms.

^bThis study merged pediatric and adult patients.³⁹

^cTime of onset is set as the starting of symptoms after the first IT injection or as the starting of symptoms after their last injection. The last injection reflects their last injection before the onset of symptoms, not the last IT of a completed cycle.

This Feature Is Available To Subscribers Only